<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Annexon Inc — News on 6ix</title>
<link>https://6ix.com/company/annexon-inc</link>
<description>Latest news and press releases for Annexon Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/annexon-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835466978dffbe2df0e2f96.webp</url>
<title>Annexon Inc</title>
<link>https://6ix.com/company/annexon-inc</link>
</image>
<item>
<title>Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of</description>
</item>
<item>
<title>Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-reports-fourth-quarter-and-year-end-2025-financial-results-portfolio-progress-and-key-anticipated-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-reports-fourth-quarter-and-year-end-2025-financial-results-portfolio-progress-and-key-anticipated-milestones</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA</description>
</item>
<item>
<title>Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-biosciences-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-biosciences-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of</description>
</item>
<item>
<title>Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-host-person-virtual-kol-130000552</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-host-person-virtual-kol-130000552</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host an in-person and virtual key opinion leader (KOL) event in New York on Wednesday, March 18, 2026, with presentations at 2:00 PM ET and a reception at 4:00 PM ET. To register, click here. The event will inc</description>
</item>
<item>
<title>Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-reports-inducement-grants-employees-220500385</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-reports-inducement-grants-employees-220500385</guid>
<pubDate>Fri, 16 Jan 2026 22:05:00 GMT</pubDate>
<description>BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635</description>
</item>
<item>
<title>Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-accelerating-next-generation-targeted-120000562</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-accelerating-next-generation-targeted-120000562</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026 Strong Financial Position Funds Operations into Late 20</description>
</item>
<item>
<title>Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-submits-tanruprubart-marketing-authorization-130000056</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-submits-tanruprubart-marketing-authorization-130000056</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it has submitted a Marketing Authorization Application</description>
</item>
<item>
<title>Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-biosciences-present-44th-annual-210500817</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-biosciences-present-44th-annual-210500817</guid>
<pubDate>Wed, 07 Jan 2026 21:05:00 GMT</pubDate>
<description>BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST. A live webcast of the event can be accessed under</description>
</item>
<item>
<title>Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-reports-inducement-grant-employee-003100178</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-reports-inducement-grant-employee-003100178</guid>
<pubDate>Wed, 17 Dec 2025 00:31:00 GMT</pubDate>
<description>BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rul</description>
</item>
<item>
<title>Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-announces-closing-public-offering-210100912</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-announces-closing-public-offering-210100912</guid>
<pubDate>Fri, 14 Nov 2025 21:01:00 GMT</pubDate>
<description>BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the closing of its previously announced underwritten public offering of 29,423,075 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 4,326,922 additional shares of</description>
</item>
<item>
<title>Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-announces-pricing-75-million-035500463</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-announces-pricing-75-million-035500463</guid>
<pubDate>Thu, 13 Nov 2025 03:55:00 GMT</pubDate>
<description>BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock at a price to the public of $2.60 per share and, in lieu of shares of common stock to certain investors,</description>
</item>
<item>
<title>Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-announces-proposed-public-offering-211200032</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-announces-proposed-public-offering-211200032</guid>
<pubDate>Wed, 12 Nov 2025 21:12:00 GMT</pubDate>
<description>BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Annex</description>
</item>
<item>
<title>Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-reports-third-quarter-2025-210500376</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-reports-third-quarter-2025-210500376</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline ARCHER II Pivotal Data for Vonaprument in Dry AMD with GA on Track for Second Half of 2026; Potent</description>
</item>
<item>
<title>Annexon Biosciences to Participate in Upcoming September Investor Conferences</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-biosciences-participate-upcoming-september-120000093</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-biosciences-participate-upcoming-september-120000093</guid>
<pubDate>Wed, 27 Aug 2025 12:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: Wells Fargo Healthcare Conference on Wednes</description>
</item>
<item>
<title>Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-reports-second-quarter-2025-200500943</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-reports-second-quarter-2025-200500943</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Kind Oral C1s In</description>
</item>
<item>
<title>Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-selected-ema-participate-product-203000200</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-selected-ema-participate-product-203000200</guid>
<pubDate>Thu, 07 Aug 2025 20:30:00 GMT</pubDate>
<description>New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development Programs in the Pilot Vonaprument Has the Potential to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Visual Structures BRISBANE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX</description>
</item>
<item>
<title>Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-announces-completion-enrollment-pivotal-110000694</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-announces-completion-enrollment-pivotal-110000694</guid>
<pubDate>Thu, 24 Jul 2025 11:00:00 GMT</pubDate>
<description>Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science and Innovation Topline Pivotal Phase 3 Data Expected in the Second Half of 2026 Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Structural Measures</description>
</item>
<item>
<title>Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-bolsters-ophthalmology-expertise-appointment-200500021</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-bolsters-ophthalmology-expertise-appointment-200500021</guid>
<pubDate>Wed, 18 Jun 2025 20:05:00 GMT</pubDate>
<description>Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and Central Retinal Photoreceptors Critical for Visual Acuity Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026 BRISBANE, Calif., June 18, 2025 (G</description>
</item>
<item>
<title>Annexon Biosciences to Present at the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-biosciences-present-jefferies-global-200500540</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-biosciences-present-jefferies-global-200500540</guid>
<pubDate>Thu, 29 May 2025 20:05:00 GMT</pubDate>
<description>BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:10 a.m. EST. A live webcast of the event can</description>
</item>
<item>
<title>Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting</title>
<link>https://6ix.com/company/annexon-inc/news/annexon-showcases-tanruprubart-data-demonstrating-200500182</link>
<guid isPermaLink="true">https://6ix.com/company/annexon-inc/news/annexon-showcases-tanruprubart-data-demonstrating-200500182</guid>
<pubDate>Mon, 19 May 2025 20:05:00 GMT</pubDate>
<description>First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster Presentations on New Pivotal Phase 3 Analyses Underscore Tanruprubart’s Rapid and Sustained Treatment Effect and Improvement in Quality of Life Compared to Placebo BRISBANE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceuti</description>
</item>
</channel>
</rss>